Dashboard
Manage Tickers

ACRSAclaris Therapeutics, Inc.

Nasdaq aclaristx.com


$ 1.17 $ -0.01 (-0.85 %)    

Friday, 09-Aug-2024 15:59:13 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 1.16
$ 1.16 x 2,400
-- x --
-- - --
$ 0.59 - $ 8.65
431,689
na
82.7M
$ 1.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-06-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 02-23-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-03-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-07-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 03-18-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-03-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 03-12-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-15-2017 12-31-2016 10-K
32 11-03-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-11-2016 03-31-2016 10-Q
35 03-23-2016 12-31-2015 10-K
36 11-18-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

aclaris-cash-cash-equivalents-and-marketable-securities-of-1499m-as-of-june-30-2024-and-265m-from-sale-of-olumiant-royalties-and-milestones-will-be-sufficient-to-fund-its-operations-into-2028
Aclaris' Cash, Cash Equivalents And Market...
08/07/2024 11:29:41

aclaris-therapeutics-q2-2024-gaap-eps-015-beats-020-estimate-sales-2766m-beat-1818m-estimate
Aclaris Therapeutics Q2 2024 GAAP EPS $(0....
08/07/2024 11:28:21

aclaris-therapeutics-and-3-other-stocks-under-2-insiders-are-buying
Aclaris Therapeutics And 3 Other Stocks Un...
07/23/2024 11:31:56

hc-wainwright--co-reiterates-neutral-on-aclaris-therapeutics
HC Wainwright & Co. Reiterates Neutral on ...
07/22/2024 10:13:06

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Neutral.

aclaris-therapeutics-sells-olumiant-royalties-and-milestones-to-omers-life-sciences-for-up-to-315m
Aclaris Therapeutics Sells OLUMIANT Royalt...
07/16/2024 20:03:23

- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -- $26.5 Million Upfront Plus Up to $5.0 M...

aclaris-therapeutics-and-1-other-stock-under-5-insiders-are-buying
Aclaris Therapeutics And 1 Other Stock Und...
07/08/2024 13:01:33

18m-bet-on-this-health-care-stock-check-out-these-3-penny-stocks-insiders-are-aggressively-buying
$1.8M Bet On This Health Care Stock? Check...
06/14/2024 11:15:34

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
05/24/2024 20:31:11

aclaris-therapeutics-q1-eps-024-beats-029-estimate-sales-240m-beat-137m-estimate
Aclaris Therapeutics Q1 EPS $(0.24) Beats ...
05/07/2024 20:02:47

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of ...

lumen-technologies-and-2-other-stocks-under-2-insiders-are-buying
Lumen Technologies And 2 Other Stocks Unde...
03/06/2024 11:56:50

The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confi...

aclaris-therapeutics-q4-earnings-insights
Aclaris Therapeutics: Q4 Earnings Insights
02/27/2024 13:55:06

aclaris-therapeutics-ati-1777-faces-uphill-battle-in-atopic-dermatitis-treatment-landscape-analyst-downgrades
Aclaris Therapeutics' ATI-1777 Faces Uphil...
01/22/2024 19:37:34

HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, comm...

why-commscope-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-mondays-mid-day-session
Why CommScope Shares Are Trading Lower By ...
01/22/2024 18:08:22

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal L...

why-coherus-biosciences-shares-are-trading-higher-by-22-here-are-20-stocks-moving-premarket
Why Coherus BioSciences Shares Are Trading...
01/22/2024 13:21:24

Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announc...

hc-wainwright--co-downgrades-aclaris-therapeutics-to-neutral
HC Wainwright & Co. Downgrades Aclaris The...
01/22/2024 12:14:49

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Aclaris Therapeutics (NASDAQ:ACRS) from Buy to Neutral.

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
01/16/2024 17:31:05

why-is-dermatology-focused-aclaris-therapeutics-stock-trading-higher-today
Why Is Dermatology Focused Aclaris Therape...
01/16/2024 16:47:48

Aclaris Therapeutics leadership changes and strategic review. Preliminary unaudited data as of Dec 31, 2023, reveals approximat...

aclaris-therapeutics-announced-that-douglas-manion-will-step-down-as-ceo-president-and-board-member-effective-immediately-the-company-has-appointed-neal-walker-aclaris-chairman-as-interim-ceo
Aclaris Therapeutics Announced That Dougla...
01/16/2024 12:10:07

the-analyst-landscape-4-takes-on-aclaris-therapeutics
The Analyst Landscape: 4 Takes On Aclaris ...
01/11/2024 19:00:17

btig-downgrades-aclaris-therapeutics-to-neutral
BTIG Downgrades Aclaris Therapeutics to Ne...
01/11/2024 13:11:31

BTIG analyst Julian Harrison downgrades Aclaris Therapeutics (NASDAQ:ACRS) from Buy to Neutral.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION